Correlations between proportion of poorly differentiated thyroid carcinoma area within cancer nodule and worse outcomes in Ramathibodi hospital
Article Sidebar
Main Article Content
Abstract
ABSTRACT
BACKGROUND: No previous studies have been published on poorly differentiated thyroid carcinoma (PDTC) in Thailand
OBJECTIVES: The aims of this study were to confirm that proportion of poorly differentiated thyroid carcinoma area more than 50% effected to the poor prognosis and to identify characteristics and prognostic factors of PDTC
METHODS: The patients treated for a PDTC between 01/2010 and 12/2019 were enrolled in this retrospective cohort study. A pathological review was done. The collected data included characteristics, treatment and outcomes. The patients were divided in the following two groups PDTC area≤ 50%(group1) and PDTC area>50%(group2). Clinico-pathological profiles and outcomes were compared between two groups
RESULTS: Sixteen patients were identified. The median age was 60 years old, with the majority being females. The median tumor size was 5.2 cm. Most patients were T3-T4 stage at the time of diagnosis, while 31.3% had nodal metastasis. This tumor usually found with co-existence tumor for example Papillary (68.8%), Follicular (12.5%), Anaplastic (6.3%). All patients were treated at least total thyroidectomy, which mostly post-operative management was radioactive iodine ablation (87.5%), radiotherapy (31.3%), Tyrosine kinase inhibitors (6.3%). The 5-year survival was 67% and 5-year relapse free survival rate was 56.8%. When we compared between two group (PDTC area≤ 50% and PDTC area>50%), the clinical profile was no statistical significance. Group 2 was high rate of death and recurrence of tumor but no statistical significance.
CONCLUSION: There is no statistical significance in the outcomes of PDTC area≤ 50% and PDTC area>50%. Larger studies are needed to increase power of the data.
Article Details
ต้นฉบับที่ส่งมาพิจารณายังวารสารหู คอ จมูก และใบหน้า จะต้องไม่อยู่ในการพิจารณาของวารสารอื่น ในขณะเดียวกันต้นฉบับที่จะส่งมาจะผ่านการอ่านโดยผู้ทรงคุณวุฒิ หากมีการวิจารณ์หรือแก้ไขจะส่งกลับไปให้ผู้เขียนตรวจสอบแก้ไขอีกครั้ง ต้นฉบับที่ผ่านการพิจารณาให้ลงตีพิมพ์ถือเป็นสมบัติของวารสารหู คอ จมูกและใบหน้า ไม่อาจนำไปลงตีพิมพ์ที่อื่นโดยไม่ได้รับอนุญาต
ตารางแผนภูมิ รูปภาพ หรือข้อความเกิน 100 คำที่คัดลอกมาจากบทความของผู้อื่น จะต้องมีใบยินยอมจากผู้เขียนหรือผู้ทรงลิขสิทธิ์นั้นๆ และใหร้ะบุกำกับไว้ในเนื้อเรื่องด้วย
References
2. Sakamoto A, Kasai N, Sugano HJC. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high‐risk group of papillary and follicular carcinomas. 1983;52(10):1849-55.
3. DeLellis RAJJoso. Pathology and genetics of thyroid carcinoma. 2006;94(8):662-9.
4. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. 2007;31(8):1256-64.
5. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8 ed. Jatin P. Shah WL, editor: Springer International Publishing; 2017. 874 p.
6. Lam K-y, Lo C-y, Chan K-w, Wan K-yJAos. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. 2000;231(3):329.
7. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, et al. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. 2007;17(7):639-46.
8. Kazaure HS, Roman SA, Sosa JAJC. Insular thyroid cancer: a population‐level analysis of patient characteristics and predictors of survival. 2012;118(13):3260-7.
9. de la Fouchardière C, Decaussin-Petrucci M, Berthiller J, Descotes F, Lopez J, Lifante J-C, et al. Predictive factors of outcome in poorly differentiated thyroid carcinomas. 2018;92:40-7.
10. Nishida T, Katayama S-i, Tsujimoto M, Nakamura J-i, Matsuda HJTAjosp. Clinicopathological significance of poorly differentiated thyroid carcinoma. 1999;23(2):205-11.
11. Dettmer M, Schmitt A, Steinert H, Haldemann A, Meili A, Moch H, et al. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? 2011;35(12):1866-72.
12. Sugitani I, Toda K, Yamamoto N, Sakamoto A, Fujimoto YJWjos. Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country. 2010;34(6):1265-73.
15. Higashino M, Ayani Y, Terada T, Kurisu Y, Hirose Y, Kawata R. Clinical features of poorly differentiated thyroid papillary carcinoma. Auris Nasus Larynx. 2019 Jun 1;46(3):437-42.
16. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, Papotti M, Bussolati G, Lloyd RV. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Modern Pathology. 2010 Sep;23(9):1269.
17. Tangjaturonrasme N, Vatanasapt P, Bychkov A. Epidemiology of head and neck cancer in Thailand. Asia Pac J Clin Oncol 2017 Aug 16 [Epub].
18. ทะเบียนมะเร็งระดับโรงพยาบาล พ.ศ.2560. แสงอริยวนิช น, editor: สถาบันมะเร็งแห่งชาติ กรมการแพทย์ กระทรวงสาธารณสุข; 2018. 2 p.
19. Kakudo K, Bai Y, Katayama S, Hirokawa M, Ito Y, Miyauchi A, et al. Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute. 2009;59(6):359-67.
20. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". Am J Surg Pathol. 1984;8(9):655-68.
21. Gnemmi V, Renaud F, Do Cao C, Salleron J, Lion G, Wemeau JL, Copin MC, Carnaille B, Leteurtre E, Pattou F, Aubert S. Poorly differentiated thyroid carcinomas: application of the Turin proposal provides prognostic results similar to those from the assessment of high‐grade features. Histopathology. 2014 Jan;64(2):263-73.
22. Thyroid Carcinoma. National Comprehensive cancer network. Available from:https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf, Accessed on October 5, 2019
23.Patel KN, Shaha AR. Poorly differentiated thyroid cancer. Current opinion in otolaryngology & head and neck surgery. 2014 Apr 1;22(2):121-6.
24 Ibrahimpasic T, Ghossein R, Shah JP, Ganly I. Poorly differentiated carcinoma of the thyroid gland: Current status and future prospects. Thyroid. 2019 Mar 1;29(3):311-21.
25. Walczyk A, Kowalska A, Sygut J. The clinical course of poorly differentiated thyroid carcinoma (insular carcinoma)-own observations. Endokrynologia Polska. 2010;61(5):467-73.
26. Sanders Jr EM, LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. World journal of surgery. 2007 May 1;31(5):934-45.
27. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology. 2003 Sep 1;21(17):3226-35.
28. Ibrahimpasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, Shaha AR, Patel SG, Tuttle RM, Shah JP, Ganly I. Outcomes in patients with poorly differentiated thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2014 Apr 1;99(4):1245-52.